Sep 24, 2024, 11:40
Neil D. Gross: Neoadjuvant immunotherapy for advanced, resectable cutaneous squamous cell carcinoma
Neil D. Gross, The Director of Clinical Research in the Department of Head and Neck Surgery at MD Anderson Cancer Center, shared a post on X:
”Latest news on neoadjuvant immunotherapy for advanced, resectable cutaneous squamous cell carcinoma presented last week at the European Society for Medical Oncology 2024, showing durable improved survival at 29.4 months. MD Anderson Cancer Center is excited to launch HN014 NRG Oncology and TROG Cancer Research.”
Source: Neil D. Gross/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Oct 13, 2024, 15:04
Oct 13, 2024, 14:56
Oct 13, 2024, 14:48
Oct 13, 2024, 14:34
Oct 13, 2024, 14:24
Oct 13, 2024, 13:33